Showing 1,541 - 1,560 results of 227,959 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( a ((non decrease) OR (a decrease)) ))', query time: 1.88s Refine Results
  1. 1541

    Retinoschisin secretion into the conditioned medium is decreased by addition of taxol. by Eiko Kitamura (349087)

    Published 2013
    “…Retinoschisin secretion into the medium decreases in a dose-dependent manner between 0.5 µM and 10 µM taxol. …”
  2. 1542
  3. 1543
  4. 1544
  5. 1545

    Decreased Core-Fucosylation Contributes to Malignancy in Gastric Cancer by Yun-Peng Zhao (551337)

    Published 2014
    “…Compared with the healthy control, a trianntenary structure abundance, peak 9 (NA3Fb), was increased significantly in gastric cancer, while the total abundance of core-fucosylated residues (sumfuc) was decreased. …”
  6. 1546
  7. 1547
  8. 1548
  9. 1549
  10. 1550

    Ischemia decreased bcl-2 content in rabbit SSM. by Qun Chen (313764)

    Published 2015
    “…<p><u>Panel A:</u> Western blotting shows that ischemia markedly decreased bcl-2 content in SSM isolated from rabbit heart compared to non-ischemic hearts. …”
  11. 1551
  12. 1552

    Forced expression of N-cadherin decreases cell survival. by Eric Haÿ (276921)

    Published 2013
    “…(B) N-cadherin silencing decreases osteoblast apoptosis. Flag cells were transfected with N-cadherin si-RNA or a non relevant si-RNA (si-NR) and treated with Wnt3a CM (15%) for 24 hours in serum deprived (1% FCS) medium and cell replication was determined. …”
  13. 1553

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…(C,D) Relative gene expression levels of HIF target genes in clear cell RCC (<i>n</i> = 10) and renal oncocytoma (<i>n</i> = 10) compared with non-diseased kidney (<i>n</i> = 12). For each gene, red indicates increased expression, blue decreased expression. …”
  14. 1554

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…Infants with a diagnosis of IUGR (n = 9) were compared to age-matched non-IUGR infants (n = 4). …”
  15. 1555
  16. 1556
  17. 1557
  18. 1558
  19. 1559

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  20. 1560